The survey provides latest insights into the status quo and future of drug product formulation and its potential to refine all steps in the biopharmaceutical value chain.
- The survey provides latest insights into the status quo and future of drug product formulation and its potential to refine all steps in the biopharmaceutical value chain.
- During a roundtable session at BIO-Europe® in Copenhagen, Rentschler Biopharma and LEUKOCARE will present key findings from the 2018 Survey ‘Formulation in the Drug Product Development Process’.
Laupheim, Germany, and Munich/Martinsried, Germany, October 18, 2018 – Rentschler Biopharma SE and LEUKOCARE AG will jointly present key findings of the 2018 Survey ‘Formulation in the Drug Product Development Process’ on November 6 at BIO-Europe® 2018 in Copenhagen, Denmark. The survey by Scrip / Informa Pharma Intelligence evaluates the status quo, importance and future of formulation and identifies key formulation needs and risks within the drug product development process. It was conducted by Rentschler Biopharma, LEUKOCARE and Pharma Intelligence in Q3/2018 among biotech and pharma companies, worldwide.
The survey covers a broad range of formulation-related topics, from key formulation aspects and considerations in drug product development to the stage of development during which companies deal with formulation as well as project failures and solutions to overcome such hurdles.
The roundtable ‘A strategic view: Formulation in the drug product development process’ will be moderated by Mike Ward, Head of Content at Informa Pharma Intelligence Insights. It will take place on Tuesday, November 6th, 2018 from 3:15 p.m. to 4:15 p.m. CET at the Bella Center in Copenhagen, Denmark. During the session, the findings of the survey will be presented and are open for discussion with the panelists and all visitors of BIO-Europe®.
About Rentschler Biopharma SE
Rentschler Biopharma SE, located in Laupheim, Germany, is a leading contract development and manufacturing organization (CDMO), focused exclusively on clients’ projects. Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer optimal solutions across the entire value chain, the company has entered into a strategic alliance for formulation development with Leukocare AG and into a strategic partnership for fill & finish with Rentschler Fill Solutions GmbH. Rentschler Biopharma is a family-owned company employing more than 850 people. For further information, please visit www.rentschler-biopharma.com.
About LEUKOCARE AG
LEUKOCARE AG provides a next-generation formulation platform for the protection of proteins like biopharmaceuticals to allow the development of better products. The proprietary Stabilizing and Protecting Solutions (SPS®) technologies are provided to development projects of partners in the pharmaceutical and medical device industry. LEUKOCARE’s SPS® technologies improve stability and quality of biologics like antibodies, viral vectors, vaccines, etc. in dry and liquid formulation including high-concentration formulations. SPS® technologies also protect proteins in biologically functionalized combination devices. For further information, please visitwww.leukocare.com.
About the Rentschler Biopharma and LEUKOCARE alliance
The alliance between Rentschler Biopharma SE and LEUKOCARE AG strategically aims to incorporate formulation development at every step throughout biopharmaceutical development and manufacturing. Working closely with the client, this will ensure the end products will – from the very beginning – have a best-in-class formulation and administration mode. This innovative approach will provide clients significant competitive advantages, enabling them to exploit the full commercial potential of their products and markets.
About BIO-Europe®
BIO-Europe® is the preeminent partnering conference of the European life science industry, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities and private one-to-one meetings. The BIO-Europe® 2018 partnering event is expected to draw over 4,000 industry attendees for three days of high-level networking, representing upwards of 2,000 companies from over 60 countries. To learn more about the conference, please visit www.ebdgroup.com/bioeurope/.
